Major Pharmaceutical Patent Litigation Wave Intensifies in Q4 2025 as Generic Manufacturers Challenge Key Drug Patents
核心洞察
The fourth quarter of 2025 witnessed an unprecedented surge in ANDA patent litigation cases, with over 80 new lawsuits filed as generic manufacturers challenged patents protecting major pharmaceutical products.
High-value drug patents faced multiple challenges, including Bayer's Kerendia (finerenone) targeted by at least 10 generic companies and AbbVie (搜索)'s Qulipta (atogepant) facing litigation from multiple manufacturers.
Settlement activity remained robust with over 50 cases resolved, often resulting in injunctions preventing generic entry until patent expiration while allowing FDA approval processes to continue.
The pharmaceutical industry experienced an intense wave of patent litigation in the fourth quarter of 2025, with more than 80 new Abbreviated New Drug Application (ANDA) cases filed across federal courts as generic drug manufacturers mounted aggressive challenges against branded pharmaceutical patents.
Kerendia Faces Coordinated Generic Challenge
Bayer Healthcare Pharmaceuticals emerged as the most litigated company during the quarter, defending its Kerendia (finerenone tablets) patent RE49,826 against at least 10 generic manufacturers. The coordinated challenge included lawsuits against Aurobindo Pharma, Teva Pharmaceuticals, Zydus Lifesciences, Apotex (搜索), Macleods Pharmaceuticals, MSN Pharmaceuticals, SABA Ilac, ScieGen Pharmaceuticals, and Dr. Reddy's Laboratories, all filed in the District of Delaware under Hon. Jennifer L. Hall.
Neurological and Rare Disease Drugs Under Pressure
Mitsubishi Tanabe Pharma (搜索) faced multiple challenges to its Radicava ORS (edaravone oral suspension) patents, with at least six generic companies filing ANDA cases including Sandoz, Shanghai Auzone Biological Technology, Cipla USA, Apotex (搜索), Lupin, and Zydus Pharmaceuticals. The litigation covers multiple patents including 10,987,341, 11,241,416, 11,478,450, 11,826,352, 11,957,660, 12,194,025, 12,285,409, and 12,310,946.
AbbVie (搜索)'s migraine (搜索) treatment Qulipta (atogepant tablets) also came under attack, with both Apotex (搜索) and Macleods Pharmaceuticals challenging patents 12,090,148, 12,350,259, 12,383,545, and 12,465,598 in separate cases filed in New Jersey federal court.
Oncology and Specialty Drug Patents Targeted
The oncology (搜索) sector saw significant litigation activity with Genentech defending its Evrysdi (risdiplam oral solution) patent 12,350,273 against Natco Pharma and its Alecensa (alectinib capsules) patents against Sun Pharmaceutical Industries. Celgene faced challenges to its Pomalyst (pomalidomide capsules) patents from Sandoz, covering patents 8,828,427, 9,993,467, and 10,555,939.
Incyte Corporation's Jakafi (ruxolitinib tablets) patents came under assault from both Dr. Reddy's Laboratories and Eugia Pharma Specialities, with litigation covering patents 7,598,257, 8,415,362, 8,722,693, 8,822,481, and 8,829,013.
Settlement Patterns Reveal Strategic Compromises
The quarter also witnessed extensive settlement activity, with over 50 ANDA litigation cases resolved through various agreements. Many settlements followed a consistent pattern where generic manufacturers acknowledged patent validity and accepted injunctions preventing market entry until patent expiration, while retaining the right to maintain Paragraph IV certifications and proceed with FDA approval processes.
Notable settlements included Gilead Sciences' resolution with Cipla regarding Biktarvy patents, where Cipla acknowledged patent validity and accepted an injunction until an agreed-upon date. Similarly, Onyx Therapeutics (搜索) reached an agreement with Somerset Therapeutics regarding Kyprolis (carfilzomib injection), with Somerset admitting patent validity and infringement.
Emerging Therapeutic Areas Draw Attention
Several cases involved newer therapeutic areas, including Oyster Point Pharma's defense of Tyrvaya (varenicline solution) patents against Lupin, and Vifor Fresenius Medical Care (搜索)'s protection of Korsuva (difelikefalin acetate injection) patents against multiple generic challengers including Gland Pharma, Cipla, and MSN Labs.
The litigation landscape also encompassed specialized formulations, with Pacira Pharmaceuticals (搜索) defending its Exparel (bupivacaine liposome injectable suspension) patents against The Whiteoak Group and Qilu Pharmaceutical, covering nine different patents related to the long-acting local anesthetic formulation.
Regulatory and Market Implications
The surge in ANDA litigation reflects the ongoing tension between branded pharmaceutical companies seeking to protect their intellectual property investments and generic manufacturers pursuing market opportunities as patents approach expiration. The settlement patterns suggest a pragmatic approach where parties balance patent protection with market access considerations, often allowing FDA approval processes to continue while maintaining exclusivity periods.
The cases span multiple therapeutic areas including cardiovascular disease (搜索), neurology (搜索), oncology (搜索), ophthalmology, and rare diseases (搜索), indicating broad generic manufacturer interest across the pharmaceutical landscape. The concentration of cases in Delaware and New Jersey federal courts continues the established pattern for pharmaceutical patent litigation venue selection.